How might consumer/patient preferences affect the process of a disease such as psoriasis? Neal Bhatia, M.D., associate clinical professor at Harbor-UCLA Medical Center and private practitioner at Therapeutics Dermatology, explored just that in a patient survey of the CeraVe product line presented at the 2018 AAD meeting.
!['[Regarding this survey], we looked at patient preference and how it might affect the process of their disease,' explained Bhatia. 'I want the patient to get the right treatment program in place. That includes a lot of moisturizing and cleansing. What's unique about CeraVe's platform is the addition of ceramides, urea and salicylic acid—all the things that ... [are] going to have a lot of impact on the disease process.'](https://img.cosmeticsandtoiletries.com/files/base/allured/all/image/2018/10/gci.Bhatia-headshot200.png?auto=format%2Ccompress&dpr=2&fit=max&q=70&w=700)
"[Regarding this survey], we looked at patient preference and how it might affect the process of their disease," explained Bhatia. "I want the patient to get the right treatment program in place. That includes a lot of moisturizing and cleansing. What's unique about CeraVe's platform is the addition of ceramides, urea and salicylic acid—all the things that ... [are] going to have a lot of impact on the disease process."This three-part podcast series is based on this study but additionally explores the differences in skin diseases, the industry's interest in the market for compromised skin, ingredient considerations and future studies.
Listen now to Part II, below; review Part I or continue to Part III.
